Emerging Frontiers in Prostate Cancer Diagnostics: Nanolaser-Guided Nanotechnology and Computational Biology for Biomarker Surveillance

Introduction: Prostate cancer remains a leading cause of cancer-related mortality in men, with early and accurate diagnosis being crucial for effective management. This review explores the convergence of nanolaser- assisted nanotechnology and computational biology as innovative strategies for biomarker surveillance in prostate cancer. Methods: A systematic review of recent peer-reviewed literature from PubMed, Scopus, and Web of Science was conducted, focusing on studies published between 2015 and 2024. Keywords included “prostate cancer,” “nanolaser diagnostics,” “nanotechnology,” “computational biology,” and “biomarker detection.” Selected articles were analyzed for advancements in diagnostic platforms, biomarker sensitivity, and integration with computational models. Results: Findings indicate that nanolaser-guided nanotechnologies offer ultra-sensitive detection of prostatespecific antigen and emerging molecular biomarkers with improved specificity compared to conventional assays. Computational biology approaches, including machine learning and systems biology models, enhance data interpretation, enable multi-biomarker integration, and support predictive analytics. Hybrid systems demonstrate potential for real-time monitoring, non-invasive sampling, and precision diagnostics. Discussion: The integration of nanolaser technologies with computational biology addresses key limitations of current diagnostic practices, including false positives, delayed detection, and limited biomarker scope. However, challenges such as scalability, regulatory approval, and standardization remain significant barriers. Collaborative research that bridges engineering, computational sciences, and clinical oncology is essential to translate these technologies into practice. Conclusion: Nanolaser-guided nanotechnology, coupled with computational biology, represents a promising frontier in prostate cancer diagnostics. Together, these tools hold the potential to advance biomarker surveillance, improve diagnostic accuracy, and pave the way for personalized oncology.